Alchemab’s Donna Finch, Head of Translational and Clinical Science, presented data on a potential first-in-class disease modifying therapeutic for Huntington’s Disease at the annual CHDI Huntington’s Disease Therapeutics Conference in Dubrovnik, Croatia, on the 26 April 2023. Our innovative, target agnostic discovery platform, which combines data analysis of hundreds of millions of individual antibodies with […]

5 November 2020 – The operating landscape has changed remarkably for many life science and technology businesses in the Cambridge Cluster since the March 23 lockdown and subsequent restrictions affecting lifestyle and working practices. Read full article

1 November 2020 – The UK BIA Antibody Taskforce, a UK consortium developing antibodies for treating COVID-19, has reached a major milestone – the identification of differentiated antibody combinations that will be taken forward for further development as an antibody cocktail. Read full article

29 October 2020 – The UK BIA Antibody Taskforce, a leading UK consortium developing antibodies for treating COVID-19 has reached a major milestone – the identification of differentiated antibody combinations that will be taken forward for further development as an antibody “cocktail”. The Taskforce developed an accelerated and rigorous multifaceted approach to create a pool […]

16 July 2020 – Three companies at Oxford’s BioEscalator are developing new detection methods and have discovered potential therapeutics in the fight against COVID-19. Even before the lockdown began, Nucleome Therapeutics, Alchemab Therapeutics and Hutano Diagnostics all quickly redirected their scientific expertise and business plans. These rapid innovations were achieved through collaborations with nearby experts, […]